\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
MONT-SAINT-GUIBERT, Belgium, July 28, 2022–(BUSINESS WIRE)–Regulatory News:
Celyad Oncology SA (Euronext
Following the press release, Celyad Oncology Control will hold a telephone convention that Friday, August 5 at 14:00 CEST / 8:00 EDT to discuss the effects of the first part of 2022 and take stock of the company’s recent advances and next steps.
Participants may call the convention at 1-201-493-6779 (international), 1-877-407-9716 (UNITED STATES) or 32(0) 800-73,904 (Belgium) and apply to join celyad Oncology SA. call.
For the live stream and archived recording, make a stop at the “Events” segment of the Celyad Oncology website.
About Celyad Oncology
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and progression of cancer cures based on chimeric antigen receptors (CAR T). ) Applicants for CAR T mobile cure for the treatment of hematological malignancies and false tumors. Celyad Oncology was founded in 2007 and founded in Mont-Saint-Guibert, Belgium and New York, NY. La company has secured investments from the Walloon region (Belgium) to help advance its CAR T mobile cure programs. For more information, visit www. celyad. com.
Forward-Looking Statement
This news release is forward-looking, within the meaning of applicable securities laws, adding the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking messages include, but are not limited to, those related to: the CYAD-101-002 trial, the addition of clinical suspension, the timing and effects of additional knowledge of the Phase 1 IMMUNICY-1 trial of CYAD-211, the protection and the clinical activity of the candidate product trial in the Celyad Oncology pipeline, the monetary condition and cash flow of Celyad Oncology, and the expected operating effects and business prospects. The words “possibly”, “may also just”, “will”, “may also just”, “should”, “should”, “plan”, “anticipate”, “intend”, “believe”, “expect” ” , “estimate”, “future”, “potential”, “continue”, “target” and similar words or expressions are intended to identify prospective email messages, although not all prospective email messages involve such identifying words . are within the existing expectations of management and would possibly involve known and unknown risks and uncertainties that may also cause the actual effects, monetary condition, functionality or achievements of Celyad Oncology to differ materially from those expressed or implied through those prospective trials. These dangers and uncertainties include, but are not limited to: the timing, duration, and final results of the clinical suspension of the Phase 1b CYAD-101-002 trial, the ability of Celyad Oncology to continue to access the percentage acquisition agreement with Lincoln Park Capital Fund, LLC, our currency and operating effects, the duration and severity of the COVID-19 pandemic and global economic uncertainty, as well as geopolitical terms and resulting sanctions due to the confrontation in Ukraine. A more detailed list and description of those hazards, uncertainties and other hazards can be found in Celyad Oncology’s filings and reports with the United States Securities and Exchange Commission (SEC), adding the most recent annual report in the Form 20-F filed with the SEC. , and upcoming presentations. and Celyad Oncology Reports. These forward-looking statements speak only as of the publication date of this document and the actual effects of Celyad Oncology may differ materially from those expressed or implied by such forward-looking statements. Celyad Oncology expressly disclaims any legal responsibility to update any forward-looking data contained herein to reflect any replacement in its expectations with respect thereto or any replacement in events, situations or cases discovered, unless required by law. law. or the regulations require.
See the businesswire. com edition: https://www. businesswire. com/news/home/20220727005051/en/
Contacts
Investor and Media Contacts: Sara ZelkovicDirector of Communications and Investor RelationsCelyad Oncologyinvestors@celyad. com